Mirae Asset Global Investments Co. Ltd. Lowers Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Mirae Asset Global Investments Co. Ltd. trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 10.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,112 shares of the company’s stock after selling 131 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Medpace were worth $379,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MEDP. Centaurus Financial Inc. increased its stake in Medpace by 2.0% in the 3rd quarter. Centaurus Financial Inc. now owns 1,513 shares of the company’s stock worth $505,000 after acquiring an additional 29 shares during the last quarter. Lindenwold Advisors INC grew its holdings in shares of Medpace by 1.6% in the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company’s stock valued at $676,000 after purchasing an additional 32 shares in the last quarter. M&T Bank Corp increased its position in Medpace by 1.2% in the third quarter. M&T Bank Corp now owns 3,199 shares of the company’s stock worth $1,068,000 after purchasing an additional 37 shares during the last quarter. Custom Index Systems LLC raised its stake in Medpace by 3.0% during the fourth quarter. Custom Index Systems LLC now owns 1,290 shares of the company’s stock valued at $429,000 after purchasing an additional 37 shares in the last quarter. Finally, Nations Financial Group Inc. IA ADV raised its stake in Medpace by 1.7% during the third quarter. Nations Financial Group Inc. IA ADV now owns 2,376 shares of the company’s stock valued at $793,000 after purchasing an additional 39 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

MEDP has been the subject of several recent research reports. Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. TD Cowen dropped their target price on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. William Blair restated an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Finally, Robert W. Baird raised their price target on Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Seven investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, Medpace has an average rating of “Hold” and a consensus target price of $381.44.

Medpace Stock Performance

NASDAQ MEDP opened at $342.41 on Friday. The company’s 50-day simple moving average is $343.70 and its two-hundred day simple moving average is $348.88. Medpace Holdings, Inc. has a one year low of $302.01 and a one year high of $459.77. The company has a market capitalization of $10.64 billion, a price-to-earnings ratio of 29.98, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 17.66% and a return on equity of 50.87%. Equities analysts expect that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.